Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
3 hedge funds and large institutions have $2.08K invested in Accelerate Diagnostics in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 40 closing their positions.
93% less funds holding
Funds holding: 43 → 3 (-40)
100% less capital invested
Capital invested by funds: $3.1M → $2.08K (-$3.1M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 40
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.32M |
| 2 |
GAM
Griffin Asset Management
New York
|
-$598K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$335K |
| 4 |
Lido Advisors
Los Angeles,
California
|
-$114K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$99.9K |
AXDX Hedge Fund Activity: Q2 2025 in Review
3 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2025, worth a combined $2.08K — down 100% from $3.1M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of AXDX and 0 opened new positions — a net loss of 40 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $1.32M sold.
- 3 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2025, down from 43 in Q1 2025.
- Funds reported $2.08K of Accelerate Diagnostics stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Accelerate Diagnostics positions in Q2 2025 and 40 closed out, a net change of -40 holders.
- The largest Accelerate Diagnostics seller in Q2 2025 was Armistice Capital, an estimated $1.32M sold.
Based on aggregated 13F filings for Q2 2025.